on a Thank programs our program. clinical now CBXXXX R&D Steve. our give you, brief with I’ll update beginning
please. slide Next
study the is appropriate currently national testing and dose, double-blind dose obesity. Xa/Xb is ascending in Phase CBXXXX pharmacokinetics the dose involved Xb stage the safety, stage. Phase a clinical complete for single ascending to So select and healthy treatment for multiple potential Phase assessment The in of most placebo-controlled of a tolerability Xa adults as
No evaluation a in double-blind assess day designed potential significant a body restarting after biomarkers Phase tolerability were safety CBXXXX in effects This study of relevant Xb or even the subjects are weight part is to level is one obese once with NASH, metabolic observed fat, disease. the that study. of of ongoing NAFLD. obesity The phase Phase and CBXXXX and liver issues to various on Xa the placebo-controlled dose of
is stage The subjects. Phase Xb currently recruiting
be recruiting that added our to third clinical activity while sites, four sites data of new All line the appeared these study the expect of meeting expedite and now the to final when order the enrollment. quarter to with the will all a single made of and this we change are three continue fast the would We have clinical new rate. study sites enroll availability of be to open function revolve subjects criteria. site entry enough but still XXXX, it of enrollment in in unlikely top addition We timing
record by updating the will the patient ClinicalTrials.gov details be but patient changes, reflect on We enrollment. not site clinical providing be to will we
finally un-blinded when occur of the the is and after analysis of is database of reminder, is and from completion study stages Phase the study locked, Xb study As will a data the the only stage. blinded both
next at As end be call, planned, obese quarterly dosing stated will the our we progress study study milestone goes updates the the milestones. last as on NAFLD would significant the on we next If the such to update expect call. the provide of in and the last likely the subject, of on progress investor
please. slide Next
XXXX. from see biomarkers. small We Now let’s What what Phase trends treatment. readouts of we do study in we about CBXXXX. for is of talk Xb for obesity MRI-PDFF weeks said This trends involving in the next study the the to as complete plan on Phase is by with depend liver fat of data quarter national in ongoing four a we next will what third in and terms reduction Xa/Xb
not will same study of larger we outcomes or So XX the with be a X Phase longer a looking XX as duration for weeks.
In that need there select planning NASH, CBXXXX outcome, a Phase the to Based dose study design to on secondary forward, be best take need of primary are need considered. to evolving regulatory for understand and in the the development and path to the factors will number or we appropriate how Xb around regimens is regimen the and most duration landscape endpoints. we the
in the NASH for carefully need patient study consider appropriate will to right diabetes potential other the of of comorbidities We and our the population population. contribution drug, study stage to select fibrosis the most and
of toxicology, process conclude GLP-X Phase cetera. additional It preparations, advantage potential in Phase be take help advantages differentiate agonist running synergy which specifically We to et to a an the also population Xb product. consider short may our with and a includes diabetic full for manufacturing, CBXXXX need X on study to us of
as to our continue final refine also So development, commercial we a will towards form. in progress we formulation
continue these for Now of indications. outcome, potential obesity NASH and at also of the the looking all alternative factors in look other and independent our at we CBXXXX we’re to
please. Next slide
talk rest let’s pipeline. now So of about our the
have and made preclinical progress have We the the great programs now stage. last in over year we peptide four
and announced these of indications. was an recently cancer first for exciting that analogs The other new is program only MBTX
as peptides the a potent movement CXC of body. or are X CXCRX. are receptor the This and family chemokine the highly of key growth and of is of that tumors type analogs cells a immune well inhibitors regulates MBTX selective Now that chemokine as within receptor metastasis the
vivo and activity successfully The will in assays mouse detail data few family an was of more has setting this next translated in And peptides also we to model of of discuss been the in cell-based the in in vitro melanoma. slides. initial demonstrated the in aggressive
those peptides idiopathic The MBTX also that announced quarterly We in analog for on started. before today. we of fibrotic we show a some announced or last a model prophylactic our And second December, established model fibrosis in already demonstrated of therapeutic on further the mouse pulmonary had the where program We’ll MBTX efficacy IPF. IPF, efficacy is fibrosis of is diseases. shared in data has of data treatment MBTX call the previously of
program the analogs vitro. third of our analogs CBXXXX potential list program last discussed is call The the family is cells final immune the And human MBTX in cells killing of with peptide cancer receptor on Enhancing meeting. the X interacts a in XXXX by type family previously cardiovascular This involved receptor, immunotherapy. on cancer homeostasis, function diabetes. at in and family the CBXXXX peptides processes. data other presented with for of key the apelin Association Diabetes We energy American the
both considerable of interest. today’s anti-fibrotic peptides, antagonists on CXCRX the on have newest Now which the I’ll call, programs, the focus and two generated
please. slide Next
cells or the a sense Now are chemical a the are send then within make that source. can chemokine towards and cell found that of proteins move corresponding signal cell surface that receptors bone The the in key and on chemokine invasion, the CXCRX within the It in angiogenesis, and the marrow. plays cells in receptor malignant therapy. cells of the a retention role and to cancer growth, particular stem homing resistance cells also metastasis, of regulates tumor message
of cancers human cancer in This inhibition CXCRX to overexpressed cells tumors. cells, immunotherapy effect in development to mobilization surveillance. ability In chemotherapy of of tumors the and immune receptor of leads tumor blocking of the evade the of of enhances is and XX% by the reduces metastatic immune various setting
potential And CXCRX cells, be for of they has dysregulated. that is can also stem for beyond offers Now where inhibition transplantation. orphan a for potential of indications so it number mobilizing treatment harvested a CXCRX this, of
What based CXCRX a genome the to inhibitors family novel novel CXCRX of discovered peptides antagonists, that be peptide a CohBar in off mitochondrial analogs. of of target and potentially risk are has first encoded is lower effects. MBTX a that the peptides the represents offers on These
than to inhibit low low to target. potent, very MBTX minimal highly are selective the concentrations able at CXCRX and range CXCRX they’re highly Our analogs they’re the
expanded potency and showed an in in we’ve in aggressive that successfully said, of demonstrated chemotherapy I efficacy on enhancing have reducing tumors. X Analog vivo. We an As already model in at we vitro initial model was this mouse melanoma MBTX growth the effective
volume with XX% fact, alone. only In MBTX for Analog by of the the XX% combination reduced mean temozolomide tumor treatment significantly with temozolomide versus X chemotherapeutic
So let’s data more look those at detail. in
Next slide.
And tumors mice. the eight for Okay, growth to see on treatment. is animals the average here time the the in each in over this left XX the presented slide implantation after of of we
the the study. sizes individual at right, tumor you On day see the XX of
the you and rapidly. dots Now the are vehicle the grew line placebo tumors control. black And treatment with see or that can a that black,
You that does vehicle. with human not inhibitors compared as I The antibody, anti-PD-X to alone. treatment like Keytruda. immune that type tumor of resulted reduction green mouse in the which can the a see this drug line from temozolomide the line equivalent is respond the blue the said, tumor in checkpoint And agent, to about particular volume aggressive XX% a chemotherapeutic is
growth XX% and the effective. the allowing invade result of reducing to grow appears a peptide This of purple and had alone expected. Now pink particular peptide tumor MBTX But line when enhanced anti-tumor growth with the effect effect tumor resulting chemotherapy modest vehicle. the the Analog as – this CXCRX, more in in line, treatment blocking combined be in reduction the compared was with ability effect tumor it’s be the successfully temozolomide, a to the significantly to on to X tumor
left we for can all animal control vehicle group rapidly. again, individual Next And each growth see top the the black On the in study. grew very tumors in please. you curves on slide in the the that see tumor this slide,
Analog tumor can the of And a that slide. right, can pink in on received you and On the all see bottom you growth. line that animals see the that showed X MBTX bottom reduction side right the temozolomide in
please. slide Next
to program, to in So shared MBTX now and announced evidence the of our the that inhibits a the cell of transition fibrosis production fibroblasts biomarkers We myofibroblasts. that last of other on of in we the vitro the analogs. family of our cells turning This anti-fibrotic peptide MBTX process cultured is from reduces call. peptides fibrotic discovery
the anti-fibrotic observed We on those fibrosis model induction of anti-fibrotic fibrosis fibrosis. and a We effects fibrosis. was efficacy was involves model indicating positive peptide after also drug that data by until setting anti-inflammatory mouse after idiopathic treating to all saw of study pulmonary A of that on the administering shared prophylactic further bleomycin. and IPF, in therapeutic outcomes MBTX lungs extended seven anti-inflammatory effects in of had effects immediately December, model days where the Back we mouse in in the of treatment been announced delayed established the without induced.
potential of ongoing Now candidate. new other goal result activity identifying this and for that family also fibrotic drug with new peptides evaluation raises the in a of the diseases
please. with and go mouse reductions not spend shared the prophylactic fibrosis treatment we time on IPF. inflammation. previously these next I’ll MBTX data of produced Showing to much significant that Let’s model in are slide the of slide, some on this but the
please. slide Next
bars followed for established. target Here delayed green with data but has down fibrosis no slows to are anorexia. blue progression for are by and off including for given IPF. from IPF, which bars are induce bleomycin nintedanib, Clinically, The until vomiting fibrosis here it the one nausea, the of red of effects nintedanib drugs IPF, where two of fibrosis. mouse normal approved The animals The currently of out is significant the was animals placebo also are data after induction treatment model therapeutic bars was treatment.
The are purple bars MBTX.
we Here positive fibrosis, study long all on and deposition outcomes, effects saw inflammation, weight. collagen
body fibrosis. the right, lost weight also bottom we the of you after normally On can see induction preserved that that’s
And of activity goal with said, I we’re the drug other for raises as a fibrotic diseases. candidate. Now this peptide new evaluating result in the identifying potential the now
slide Let’s to go the next please.
such our overview of the first here Behind of So an both peptides high programs MBTX Phase various And cancer for clinical clinical is MBTX fibrotic R&D obesity. list for as for analogs relevant activity and a testing with to efficacy Xb preclinical of the CXCRX studies. X our data is programs expanding that slide candidate level cancer the is IPF, the and include the CBXXXX antagonist type current these MBTs. this NASH for analogs in in indications, other for immunotherapy animal CBXXXX, analogs for and diseases stage diabetes.
with And the back to hand presentation I’ll Steve. that
